Thyrocare Technologies Ltd

Stage 3 · Topping · week 1

As of 16 Oct 2026, Thyrocare Technologies is in Stage 3 — topping, where an uptrend loses steam, in its first week (since 13 Oct 2026). It closed at ₹485, 25.3% below its 52-week high and below its 200-day average, which is rising. In Health Care, 40.6% of stocks are in Stage 2.

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. More about the company

₹485.3
-0.47% today
₹7,723 Cr · Mid cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dHospitals & Diagnostic Centres 19.4%-19.4 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is THYROCARE early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-25.3%
₹349.6 lo₹649.4 hi
25.3% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 1
1w13w26w
Week 1 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-0.1%
200 DMA: ₹485.8 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.46x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -4.9% vs MA50 -1.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-10.4%
3M
-6.8%
6M
+23.1%
YTD
+7.1%
1Y
+18.9%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
19.4%
20d Δ
-19.4pp
1M return
-10.4%
3M return
-12.2%
Industry Stage-2 % · last 20 days
Industry has 5 Stage 2 leaders. See Hospitals & Diagnostic Centres Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 18w
S2 30w
S2 20w
S2 19w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 10w → S3 5w → S2 18w → S3 5w → S2 4w → S3 4w → S2 30w → S3 6w → S4 9w → S1 4w → S2 20w → S3 3w → S2 11w → S3 7w → S4 8w → S1 3w → S2 19w → S3 1w current
Total tracked: 169 weeks across 19 stage runs.
Scan Membership
Prop Scan
Latest: 2026-09-04
Pullback Hunter
Latest: 2026-08-21
60 appearances in last 60 days. First seen: 2026-07-08.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S3
Wk 1 · Vol 0.46x
2026-10-15S3
Wk 1 · Vol 0.54x
2026-10-14S3
Wk 1 · Vol 0.51x
2026-10-13S32→3
Wk 1 · Vol 0.55x
2026-10-12S2
Wk 18 · Vol 0.93x
2026-10-09S2
Wk 18 · Vol 0.69x
2026-10-08S2
Wk 18 · Vol 1.76x
2026-10-07S2
Wk 18 · Vol 0.56x
2026-10-06S2
Wk 18 · Vol 0.19x
2026-10-05S2
Wk 17 · Vol 0.26x
2026-10-01S2
Wk 17 · Vol 0.27x
2026-09-30S2
Wk 17 · Vol 0.29x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹565.4
200 DMA
₹485.8
52W High
₹649.4
52W Low
₹349.6
5D Low
₹485.3
Resistance levels (recent highs)
20d High
₹577.5
60d High
₹649.4
120d High
₹649.4
250d High
₹649.4
Next resistance
+19.0%
to 20d High
Ask the Market AI about THYROCAREAsk →
P/E (TTM)
50.0
Forward 37.5
Earnings Growth (YoY)
+116.4%
Revenue +19.7%
ROE
+28.7%
Profit margin +19.7%
Dividend Yield
1.86%
P/B 15.2
About this companyHealth Care· Hospitals & Diagnostic Centres

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of testing equipment and consumables; and glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.